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SObjective: The purpose of this study was to clarify the role and clinical significance of metastasis associated in
colon cancer 1 in resected stage I non–small cell lung cancers.
Methods: Tumor specimens were collected from 146 consecutive patients who underwent a complete resection
for stage I lung adenocarcinoma from 1998 to 2007 at the University of Occupational and Environmental Health.
We analyzed the expression of metastasis associated in colon cancer 1 mRNA of primary lung adenocarcinomas
by real-time reverse transcriptase-polymerase chain reaction.
Results: The average postoperative observation period was 49.4 months. Thirteen (8.9%) of 146 patients had
recurrences after surgery. Overexpression of metastasis associated in colon cancer 1 mRNAwas identified in 62
patients (42.5%). Metastasis associated in colon cancer 1 was overexpressed in 9 (69.2%) of 13 patients and 53
(39.9%) of 133 patients with and without recurrence, respectively (P¼ .004). The median metastasis associated
in colon cancer 1 copy number was 3.0 and 1.4 in patients with and without tumor recurrence, respectively. Me-
tastasis associated in colon cancer 1 overexpression was associated with poorer disease-free survival according
to the survival analysis (P ¼ .033).
Conclusions:Metastasis associated in colon cancer 1 gene overexpressionmay be a useful marker for predicting
postoperative recurrence in patients with lung adenocarcinoma after surgery. (J Thorac Cardiovasc Surg
2011;141:895-8)Earn CME credits at
http://cme.ctsnetjournals.org
The benefits of adjuvant chemotherapy have been primarily
demonstrated using cisplatin-based chemotherapy.1 How-
ever, the 5-year survival of patients with resected stage IB
non–small cell lung cancers is up to 74% without adjuvant
chemotherapy, suggesting that not all patients require
chemotherapy after a complete resection.2 Therefore, it is
necessary to identify the patients who will benefit the
most from postoperative adjuvant chemotherapy to pre-
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The Journal of Thoracic and Caand to prevent adverse events in those who do not require
treatment. Therefore, it is important to evaluate the biolog-
ical and molecular characteristics of non–small cell lung
cancers to identify the factors related to recurrence after
surgery. However, no useful markers to predict clinical
recurrence are currently known.
The metastasis associated in colon cancer 1 (MACC1)
gene was identified by differential display reverse
transcriptase-polymerase chain reaction (PCR) by analyzing
the colon mucosa, primary tumors, and metastatic lesions of
patients with colorectal cancers (CRCs).3 MACC1 expres-
sionwas reported to be a predictor of tumorgrowth, invasion,
andmetastasis, and to predict tumor recurrence in colon can-
cer.4 Lung adenocarcinomas are similar to CRCs in regard to
histologic type and carcinogenesis. We therefore hypothe-
sized that MACC1 may be a useful prognostic indicator of
tumor recurrence in patients after lung adenocarcinoma
resection. The purpose of the current study was to clarify
the role of MACC1 in lung adenocarcinomas.
MATERIALS AND METHODS
Patients and Clinical Features
Tumor samples were obtained from 494 consecutive patients with
primary lung adenocarcinomas who had undergone surgical resection be-
tween 1998 and 2007 at the University of Occupational and Environmental
Health. Fifty-six patients had an incomplete resection. The tumor samples
from 57 patients were too small to extract sufficient levels of DNA for the
analyses. A total of 108 patients had overlapping other organs or multiple
lung cancers, and 13 patients died of other causes without recurrence.rdiovascular Surgery c Volume 141, Number 4 895
TABLE 2. Relationships between MACC1 overexpression and
clinicopathologic characteristics
MACC1 overexpression
Variables Category
No. of patients
n ¼ 146
Positive (%)
62 (42.5)
Negative
84
Gender Male 77 39 (50.6) 38
Female 69 23 (33.3) 46
Age (y) 69 77 33 (42.9) 44
>69 69 29 (42.0) 40
pT T1 116 49 (42.2) 67
T2-4 30 13 (43.3) 17
pT, Pathologic T status; MACC1, metastasis associated in colon cancer 1.
Abbreviations and Acronyms
CRC ¼ colorectal cancer
DFS ¼ disease-free survival
MACC1¼metastasis associated in colon cancer 1
PCR ¼ polymerase chain reaction
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SFifty-four patients had pathologic diagnoses of stage II to IV tumors. As
a result, 348 patients were excluded from the analyses. A total of 146 pa-
tients were included in the present series. All patients were Japanese. There
were 77 male subjects and 69 female subjects in the current series, with
a mean age of 68.3 years (range, 40–91 years). The tumor stage was clas-
sified according to the new TNM (7th edition) classification for lung can-
cer.5 According to the pathologic stage, 116 patients had stage IA tumors,
including 71 with stage T1a, 45 with stage T1b, and 30 with stage IB (T2a).
The operative procedures included a lobectomy in 133 patients, segmentec-
tomy partial resection in 5 patients, partial resection in 5 patients, lobec-
tomy plus partial resection in 2 patients, and lobectomy plus
segmentectomy in 1 patient. No patients had received chemotherapy or ra-
diotherapy before the resection. Nine patients (6.2%) had received adju-
vant chemotherapy (7 patients received carboplatin plus paclitaxel, 1
patient received carboplatin plus gemcitabine, and 1 patient received
tegafur-uracil). The average postoperative observation period was 51.1
months, ranging from 1.8 to 126.5 months. Thirteen (8.9%) of 146 patients
had recurrences after surgery.
We investigated MACC1 overexpression, the relationship between
MACC1 overexpression and clinicopathologic factors, and the recurrence
rate by MACC1 discrimination after surgery in patients with lung adeno-
carcinoma. The institutional review board’s approved informed consent
for the use of the tumor specimens, data collection, and analysis was ob-
tained from the patients or their legal guardian(s). Patients were followed
up every month within the first postoperative year and at approximately
2- to 4-month intervals thereafter. Evaluations included physical examina-
tion, chest roentgenography, blood chemistry analysis, andmeasurement ofTABLE 1. Expression of MACC1 mRNA in normal tissue
Organ Expression
Adrenal gland 0.0055
Bone marrow 0.1329
Bronchus 0.3192
Colon 0.0502
Fetal brain 0.0045
Fetal liver 0.0161
Heart 0.0651
Kidney 1.8185
Liver 0.0433
Lung 1.0024
Placenta 0.0854
Prostate 0.6149
Salivary gland 0.9055
Skeletal muscle 0.0024
Spinal cord 0.0049
Testis 0.1441
Thymus 0.0295
Thyroid gland 0.6212
Uterus 0.0049
Whole brain 0.0079
MACC1, Metastasis associated in colon cancer 1.
896 The Journal of Thoracic and Cardiovascular Surgtumor markers (eg, carcinoembryonic antigen, CYFRA, and squamous cell
carcinoma). Chest and abdominal computed tomography, brain magnetic
resonance imaging, and a bone scintiscan were performed every 6 months
for 3 years after surgery. Additional examinations were performed if any
symptoms or signs of recurrence were detected.
Detection of MACC1 Overexpression
MACC1 overexpression was analyzed in all samples by quantitative
real-time PCR, performed on a StepOnePlus Real-Time PCR System (Ap-
plied Biosystems, Foster City, Calif) using a Fast SYBR GreenMaster Mix
(Applied Biosystems). Gene expression was quantified by comparing the
levels of the target gene with the levels of beta actin as an internal control.
Quantification was based on a standard curve generated from human nor-
mal genomic DNA by previously described methods.6 The relative
MACC1 copy number was also normalized to human genomic DNA.
The change in the copy number of the MACC1 gene relative to actin and
the calibrator DNA were determined by the following formula: (tumor-
MACC1/tumor-beta actin)/(control-MACC1/control-beta actin). PCR for
each primer set was performed in triplicate, and the means were reported.
The conditions for the quantitative PCR reactions were as follows: 1 cycle
of 95C for 20 seconds, 40 cycles of 95C for 3 seconds, and 60C for 30
seconds. At the end of the PCR, the samples were subjected to a melting
analysis to confirm the specificity of the amplicon. The primer sequences
used in the present study for the MACC1 gene were as follows: forward,
TTCTTTTGATTCCTCCGGTGA, and reverse, ACTCTGATGGG-
CATGTGCTG.3 A commercially available panel of total RNA (Clontech
Laboratories Inc, Palo Alto, Calif) obtained from 20 normal tissues was
used. We assigned a score of 1.0 as the MACC1 gene copy number present
in normal lung tissues.
Statistical Analysis
Statistical significance was evaluated using the chi-square or Fisher’s
exact test. The odds ratio and 95% confidence interval were calculated
for each variable. The Kaplan–Meier method was used to estimate the
probability of survival, and survival differences were analyzed by the
log-rank test. A multivariate analysis was then performed according toTABLE 3. Recurrent sites of tumors
Hematogenous (n ¼ 9*) Site No.y
Brain 1
Lung 7
Adrenal 1
Skin 1
Liver 1
Locoregional (n ¼ 5) Lymph node 3
Pleural dissemination 2
*One patient had recurrent tumors in the brain and adrenal gland, and 1 patient had
recurrent tumors in the lung and liver. yThe number of recurrent sites overlapped.
ery c April 2011
TABLE 4. Relationships between MACC1 overexpression and
recurrence
MACC1 overexpression
Variables Positive (%) 62 (42.5) Negative 84
Cases with recurrence 9 (69.2) 4
Cases without recurrence 53 (39.9) 80
MACC1, Metastasis associated in colon cancer 1.
TABLE 5. Univariate analysis using a proportional hazard model for
disease-free survival
Characteristics Hazard
ratio 95% CI
P
valueVariables Unfavorable Favorable
Gender Male Female 1.767 0.543–5.747 .334
Age (y) 69 >69 0.963 0.323–2.876 .947
T status T2a T1 2.695 0.882–8.264 .082
MACC1
overexpression
Positive Negative 3.356 1.031–10.870 .044
CI, Confidence interval; MACC1, metastasis associated in colon cancer 1.
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SCox’s proportional hazards model. Data were analyzed using the StatView
software package (Abacus Concepts, Inc, Berkeley, CA).
RESULTS
Detection of MACC1 Overexpression
The maximum MACC1 overexpression in normal tissue
was 1.82 in the kidney, compared with the value of 1.0
defined for normal lung tissue (Table 1). Therefore, we as-
signed a cutoff value of 2.0 for MACC1 overexpression,
which was defined as 2 or more copies. Furthermore, 5
(71.4%) of 7 metastatic lung tumors from CRCs were con-
firmed to have overexpressed MACC1 expression (data not
shown). MACC1 overexpression was present in the tumors
of 93 patients (46.5%). There was no significant association
ofMACC1overexpressionwith the clinical factors (Table 2).
Relationships Between MACC1 Overexpression and
Recurrence
The majority of the sites of tumor recurrence were hema-
togenous metastases (Table 3). MACC1 was overexpressed
in 9 (69.2%) of 13 patients and 53 (39.9%) of 133 patients
with and without recurrence, respectively (P ¼ .004)
(Table 4). The median MACC1 copy number was 3.0 in
patients with tumor recurrence and 1.4 in patients without
recurrence.
Prognosis of Patients According to Molecular
Parameters
The 5-year disease-free survival (DFS) for those with
negative and positive MACC1 overexpression was 97.4%0
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FIGURE 1. Kaplan–Meier DFS curves stratified by MACC1 expression.
The positive (heavy lines) and negative (narrow lines) expression of
MACC1. MACC1, Metastasis associated in colon cancer 1.
The Journal of Thoracic and Caand 85.4%, respectively (P ¼ .033) (Figure 1). MACC1
overexpression was associated with poorer DFS according
to the univariate survival analysis (P ¼ .044) (Table 5).
We also divided the tertile classification and analysis by
the division of the approximate number of the patients:
less than 1.0 (n ¼ 39), more than 1.0 but less than 3.0
(n ¼ 50), and more than 3.0 (n ¼ 57). The 5-year DFS of
the less than 1.0, more than 1.0 but less than 3.0, and
more than 3.0, for MACC1 overexpression, was 97.4%,
95.9%, and 86.2%, respectively. Multivariate analysis
showed a P value of .044 when divided by the number of
specimens with positive or negative MACC1 expression.
The P value was .621 when divided by the number with
more than 1.0 or less than 1.0, and the P value was .201
when divided by the number more than 3.0 or less than
3.0 (Table 6).DISCUSSION
Clinical findings and current tissue-based molecular
markers are insufficient for the early identification of indi-
viduals at high risk for metastasis.7 Therefore, novel strate-
gies for prevention of metastasis are urgently required to
improve the prognosis and quality of life for patients with
cancer. MACC1 was recently identified as an important
prognostic factor of metastatic disease in CRC.3 In addition,
MACC1 is located on chromosome 7p21.1 and regulates tis-
sue growth via the hepatocyte growth factor/MET signaling
pathway.4 Hepatocyte growth factor/METoverexpression is
an important predictor of the response of patients with lung
adenocarcinoma treated with an epidermal growth factor
receptor-tyrosine kinase inhibitor.8 Notably, polysomy of
chromosome 7 is a common finding in both lung cancers
and CRC tumors.9-11 Therefore, we hypothesized that the
incidence of MACC1 overexpression would be higher in
recurrent cases after surgery because these share the same
histology and carcinogenesis resembles CRC. If this is the
case, then this subgroup of patients with stage I should be
selected for adjuvant chemotherapy with priority as
higher risk.
The current study is the first to demonstrate the molecular
analysis of MACC1 overexpression and correlate this gene
to the prognosis of patients with lung adenocarcinoma. Therdiovascular Surgery c Volume 141, Number 4 897
TABLE 6. Multivariate analysis using a proportional hazard model for disease-free survival
Characteristics
Variables Unfavorable Favorable Hazard ratio 95% CI P value
Model 1
T status T2a T1 2.741 0.886–8.333 .081
MACC1 overexpression Positive Negative 3.3675 1.034–10.989 .044
Model 2
T status T2a T1 2.564 0.828–7.937 .103
MACC1 overexpression >1.0 <1.0 1.470 0.319–6.770 .621
Model 3
T status T2a T1 2.725 0.889–8.333 .079
MACC1 overexpression >3.0 <3.0 2.044 0.684–6.107 .201
CI, Confidence interval; MACC1, metastasis associated in colon cancer 1.
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Sresults show that the incidence of MACC1 overexpression
was significantly higher in recurrent cases than in non-
recurrent cases. Furthermore, MACC1 overexpression was
associated with poorer DFS (Figure 1). Stein and col-
leagues3 reported a 5-year survival of 80% for patients
with low MACC1-expressing tumors, but only 15% for in-
dividuals with high MACC1-expressing primary tumors,
which was consistent with our results. The biological find-
ings in lung adenocarcinoma suggested a sequential pro-
gression from localized bronchioloalveolar carcinomas
during the course of pulmonary adenocarcinogenesis.12
These carcinogenesis events seem similar to the transition
from adenoma to carcinoma in CRCs.4 However, the reason
for the difference in predictability byMACC1 between lung
adenocarcinoma and CRC still remains to be elucidated.
This finding suggests that MACC1 overexpression may be
a suitable biomarker to identify those candidates whowould
benefit most from adjuvant chemotherapy in stage I adeno-
carcinoma after complete resection.
CONCLUSIONS
MACC1 overexpression has the potential to be a predictor
of postoperative tumor recurrence in lung adenocarcinoma
after complete resection. However, the present study had 2
limitations: (1) This was a retrospective study performed at
a single institution, and (2) not all models by multivariate
analysis demonstrated that MACC1 overexpression was
independently associated with poor patient survival. To
overcome these limitations, further exploratory studies of
biomarkers are required to predict tumor recurrence after
pulmonary resection.
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